... preparations. In addition, tramadol and paracetamol were found to reduce the severity of pain and photophobia associated with moderate-to-severe migraine headache [97]. Intra-operative studies showed tramadol did not antagonise the hypnotic effects of volatile inhalational agents (such as isoflurane ...
Buprenorphine (with or without naloxone)
... At sufficient doses, methadone alleviates opioid withdrawal and the need for additional illicit ‘use on top’. However, if illicit opioids are used, they will produce additional opioid effects if they are able to reach the receptor sites. Buprenorphine, with its high affinity for the opioid receptor ...
... At sufficient doses, methadone alleviates opioid withdrawal and the need for additional illicit ‘use on top’. However, if illicit opioids are used, they will produce additional opioid effects if they are able to reach the receptor sites. Buprenorphine, with its high affinity for the opioid receptor ...
Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5
... conditions and procedures. Some of its uses are for pupillary dilation in uveitis (to prevent or aid in the disruption of posterior synechia formation), for many ophthalmic surgical procedures and for refraction without cycloplegia. Phenylephrine Hydrochloride Ophthalmic Solution may also be used fo ...
... conditions and procedures. Some of its uses are for pupillary dilation in uveitis (to prevent or aid in the disruption of posterior synechia formation), for many ophthalmic surgical procedures and for refraction without cycloplegia. Phenylephrine Hydrochloride Ophthalmic Solution may also be used fo ...
[Product Monograph Template
... Naloxone Hydrochloride Nasal Spray is for intranasal use only. No additional device assembly is required. Because treatment of suspected opioid overdose must be performed by someone other than the patient, be sure to inform caregivers, family members, and other persons around the patient about the p ...
... Naloxone Hydrochloride Nasal Spray is for intranasal use only. No additional device assembly is required. Because treatment of suspected opioid overdose must be performed by someone other than the patient, be sure to inform caregivers, family members, and other persons around the patient about the p ...
10 mg/5 mL Morphine Sulfate Oral Solution
... WARNING: RISK OF MEDICATION ERRORS See full prescribing information for complete boxed warning Morphine sulfate oral solution is available in 10 mg per 5 mL and 20 mg per 5 mL concentrations. Take care to avoid dosing errors due to confusion between different concentrations and between mg and mL, wh ...
... WARNING: RISK OF MEDICATION ERRORS See full prescribing information for complete boxed warning Morphine sulfate oral solution is available in 10 mg per 5 mL and 20 mg per 5 mL concentrations. Take care to avoid dosing errors due to confusion between different concentrations and between mg and mL, wh ...
Morphine Sulfate Oral Solution
... WARNING: RISK OF MEDICATION ERRORS See full prescribing information for complete boxed warning Morphine sulfate oral solution is available in 10 mg per 5 mL and 20 mg per 5 mL concentrations. Take care to avoid dosing errors due to confusion between different concentrations and between mg and mL, wh ...
... WARNING: RISK OF MEDICATION ERRORS See full prescribing information for complete boxed warning Morphine sulfate oral solution is available in 10 mg per 5 mL and 20 mg per 5 mL concentrations. Take care to avoid dosing errors due to confusion between different concentrations and between mg and mL, wh ...
new zealand data sheet
... following opioid administration for the management of pain is rare. Fentanyl can be abused in a manner similar to other opioid agonists. Abuse or intentional misuse of fentanyl transdermal patches may result in overdose and/or death. Patients with a prior history of drug dependence/alcohol abuse are ...
... following opioid administration for the management of pain is rare. Fentanyl can be abused in a manner similar to other opioid agonists. Abuse or intentional misuse of fentanyl transdermal patches may result in overdose and/or death. Patients with a prior history of drug dependence/alcohol abuse are ...
HIGHLIGHTS OF PRESCRIBING
... approach is advised when determining the total daily dose of morphine sulfate. It is better to underestimate a patient’s 24hour oral morphine sulfate dose and make available rescue medication than to overestimate the 24-hour oral morphine sulfate dose and manage an adverse experience of overdose. Co ...
... approach is advised when determining the total daily dose of morphine sulfate. It is better to underestimate a patient’s 24hour oral morphine sulfate dose and make available rescue medication than to overestimate the 24-hour oral morphine sulfate dose and manage an adverse experience of overdose. Co ...
Cytochrome P450 2D6 (CYP2D6) Pharmacogenetic
... • Convert codeine to morphine at a greater extent than normal leading to an increased risk of toxic side effects, such as over sedation or respiratory depression • Because infants may be more susceptible to adverse effects from morphine, breastfeeding mothers who are ultra-rapid metabolizers should ...
... • Convert codeine to morphine at a greater extent than normal leading to an increased risk of toxic side effects, such as over sedation or respiratory depression • Because infants may be more susceptible to adverse effects from morphine, breastfeeding mothers who are ultra-rapid metabolizers should ...
Cytochrome P450 2D6 (CYP2D6) Pharmacogenetic Competency
... • Convert codeine to morphine at a greater extent than normal leading to an increased risk of toxic side effects, such as over sedation or respiratory depression • Because infants may be more susceptible to adverse effects from morphine, breastfeeding mothers who are ultra-rapid metabolizers should ...
... • Convert codeine to morphine at a greater extent than normal leading to an increased risk of toxic side effects, such as over sedation or respiratory depression • Because infants may be more susceptible to adverse effects from morphine, breastfeeding mothers who are ultra-rapid metabolizers should ...
diamorphine hydrochloride bp 5 mg lyophilisate for solution for
... Diamorphine has been used in the treatment of terminally ill children. Diamorphine has been administered in reduced doses to children with neoplastic disease when it becomes difficult to give treatment orally. The starting dose should be selected according to age, size, symptoms and previous analges ...
... Diamorphine has been used in the treatment of terminally ill children. Diamorphine has been administered in reduced doses to children with neoplastic disease when it becomes difficult to give treatment orally. The starting dose should be selected according to age, size, symptoms and previous analges ...
Rx Only Cyclobenzaprine Hydrochloride Extended
... • Hypersensitivity to any component of this product. • Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. • Hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants ...
... • Hypersensitivity to any component of this product. • Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. • Hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants ...
Oxycodone-Naloxone Acino Prolonged
... The maximum daily dose of Oxycodone/Naloxone Acino is 160 mg oxycodone hydrochloride and 80 mg naloxone hydrochloride. The maximum daily dose is reserved for patients who have previously been maintained on a stable daily dose of oxycodone/naloxone and who have become in need of an increased dose. Sp ...
... The maximum daily dose of Oxycodone/Naloxone Acino is 160 mg oxycodone hydrochloride and 80 mg naloxone hydrochloride. The maximum daily dose is reserved for patients who have previously been maintained on a stable daily dose of oxycodone/naloxone and who have become in need of an increased dose. Sp ...
Prescribing Info - American Regent
... acetylcysteine is related to the sulfhydryl group in the molecule. This group probably “opens” disulfide linkages in mucus thereby lowering the viscosity. The mucolytic activity of acetylcysteine is unaltered by the presence of DNA, and increases with increasing pH. Significant mucolysis occurs betw ...
... acetylcysteine is related to the sulfhydryl group in the molecule. This group probably “opens” disulfide linkages in mucus thereby lowering the viscosity. The mucolytic activity of acetylcysteine is unaltered by the presence of DNA, and increases with increasing pH. Significant mucolysis occurs betw ...
Pharmacogenetic Determinants of Codeine Induction by Rifampin
... The effect on respiration, pupillary diameter and psychomotor performance was assessed on each study day 0.5, 1, 1.5, 2, 3, 4, 5 and 6 h after the intake of codeine. Three pharmacodynamic measurements were performed before the administration of codeine, and the average was taken as the base-line val ...
... The effect on respiration, pupillary diameter and psychomotor performance was assessed on each study day 0.5, 1, 1.5, 2, 3, 4, 5 and 6 h after the intake of codeine. Three pharmacodynamic measurements were performed before the administration of codeine, and the average was taken as the base-line val ...
PRODUCT MONOGRAPH Pilocarpine Hydrochloride Tablets, USP
... Patients with mild and moderate hepatic impairment should begin treatment at a reduced daily dose, gradually increasing the dosage up to 5 mg three to four times daily as safety and tolerability allow. (See DOSAGE AND ADMINISTRATION). No pharmacokinetic data are available for any dose of pilocarpine ...
... Patients with mild and moderate hepatic impairment should begin treatment at a reduced daily dose, gradually increasing the dosage up to 5 mg three to four times daily as safety and tolerability allow. (See DOSAGE AND ADMINISTRATION). No pharmacokinetic data are available for any dose of pilocarpine ...
methotrexate - Cancer Care Ontario
... evacuated before treatment with methotrexate. Myelosuppression may develop with any dosage schedule, but is more severe with high doses, daily administration of lower doses, in malnourished patients, in patients with decreased renal function and in patients with effusions, ascites or significant ede ...
... evacuated before treatment with methotrexate. Myelosuppression may develop with any dosage schedule, but is more severe with high doses, daily administration of lower doses, in malnourished patients, in patients with decreased renal function and in patients with effusions, ascites or significant ede ...
Investigating the efficacy and safety of over-the
... codeine combination analgesics for the treatment of any pain condition or as an anti-tussive. MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, CENTRAL, CINAHL and PsycINFO (inception to end December 2015) were searched for randomised controlled trials (RCTs). Two authors independently extra ...
... codeine combination analgesics for the treatment of any pain condition or as an anti-tussive. MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, CENTRAL, CINAHL and PsycINFO (inception to end December 2015) were searched for randomised controlled trials (RCTs). Two authors independently extra ...
Gamma Hydroxybutyric Acid (GHB) Intoxication Abstract 730
... free radicals.2,5,6 Despite promising beneficial effects in basic science research, GHB has not found widespread clinical use. In the 1960–70’s, GHB was used as a general anesthetic agent but fell out of favor due to an association with abnormal electroencephalographic (EEG) patterns in animals.7,8 ...
... free radicals.2,5,6 Despite promising beneficial effects in basic science research, GHB has not found widespread clinical use. In the 1960–70’s, GHB was used as a general anesthetic agent but fell out of favor due to an association with abnormal electroencephalographic (EEG) patterns in animals.7,8 ...
Chloral Hydrate Mixture 1g/10mL
... Alertness: Chloral hydrate may impair mental and/or physical abilities, and may cause drowsiness which may persist the next day. Patients should therefore be cautioned about performing activities requiring mental alertness or physical coordination (e.g. operating machinery or driving). Dependence: T ...
... Alertness: Chloral hydrate may impair mental and/or physical abilities, and may cause drowsiness which may persist the next day. Patients should therefore be cautioned about performing activities requiring mental alertness or physical coordination (e.g. operating machinery or driving). Dependence: T ...
Clinical and pharmacological evaluation of buprenorphine and
... same combination was taken illicitly by a parenteral route, it would have the opposite effects, precipitating substantial opiate withdrawal. This was an unusual requirement for a new drug formulation. In general, successful medications do not produce unpleasant effects and exhibit minimal interindiv ...
... same combination was taken illicitly by a parenteral route, it would have the opposite effects, precipitating substantial opiate withdrawal. This was an unusual requirement for a new drug formulation. In general, successful medications do not produce unpleasant effects and exhibit minimal interindiv ...
DILT-XR - Apotex
... the competitive inhibition of metabolism. Especially in patients with renal and/or hepatic ...
... the competitive inhibition of metabolism. Especially in patients with renal and/or hepatic ...
ACETYLCYSTEINE Solution, USP
... In a teratology study of acetylcysteine in the rabbit, oral doses of 500 mg/kg/day (2.6 times the human mucolytic dose) were administered to pregnant does by intubation on days 6 through 16 of gestation. Acetylcysteine was found to be nonteratogenic under the conditions of study. In the rabbit, two ...
... In a teratology study of acetylcysteine in the rabbit, oral doses of 500 mg/kg/day (2.6 times the human mucolytic dose) were administered to pregnant does by intubation on days 6 through 16 of gestation. Acetylcysteine was found to be nonteratogenic under the conditions of study. In the rabbit, two ...
Preview the material
... was one of the most common drugs taken in an overdose with intent to cause self-harm, accounting for almost 17% of the fatalities,1 and therapeutic errors with acetaminophen that caused liver damage were quite common.1 Acetaminophen (the drug is called paracetamol in Europe) overdose is now the most ...
... was one of the most common drugs taken in an overdose with intent to cause self-harm, accounting for almost 17% of the fatalities,1 and therapeutic errors with acetaminophen that caused liver damage were quite common.1 Acetaminophen (the drug is called paracetamol in Europe) overdose is now the most ...
Dextropropoxyphene
Dextropropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company. It is an optical isomer of levopropoxyphene. It is intended to treat mild pain and also has antitussive (cough suppressant) and local anaesthetic effects. The drug has been taken off the market in Europe and the US due to concerns of fatal overdoses and heart arrhythmias. Its onset of analgesia (pain relief) is said to be 20–30 minutes and peak effects are seen about 1.5–2 hours after oral administration.Dextropropoxyphene is sometimes combined with acetaminophen or aspirin. Trade names include Darvocet-N and Di-Gesic, Darvon with APAP (for dextropropoxyphene and paracetamol) and Darvon with ASA (for dextropropoxyphene and aspirin). The British approved name (i.e. the generic name of the active ingredient) of the paracetamol/dextropropoxyphene preparation is ""co-proxamol"" (sold under a variety of brand names); however, it has been withdrawn since 2007, and is no longer available to new patients, with exceptions. The paracetamol combination(s) are known as Capadex or Di-Gesic in Australia, Lentogesic in South Africa, and Di-Antalvic in France (unlike co-proxamol, which is an approved name, these are all brand names).Dextropropoxyphene is known under several synonyms, including: Alpha-d-4-dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate [(2S,3S)-4-(Dimethylamino)-3- methyl-1,2-diphenylbutan-2-yl] propanoate (+)-1,2-Diphenyl-2-propionoxy- 3-methyl-4-di-methylaminobutane Desoxypropiophen↑ 1.0 1.1 1.2 1.3 1.4 ↑ ↑ ↑ ↑ ↑ ↑ ↑